AU
UK
CA
US
IND
NZ
Promisia Healthcare Limited (NZX:PHL) has upgraded its FY26 earnings guidance, increasing its forecast for underlying EBITDAF for the year ending 31 March 2026. The company now expects earnings before interest, tax, depreciation, amortisation and fair value adjustments to range betweenNZD 6.4 million and NZD …
Ryman Healthcare Ltd (NZX:RYM)on Tuesday released its refreshed strategy, new capital management framework, and updateddividendpolicy at its Investor Day for investors and analysts. The announcement outlines the company’s priorities across cash flow generation, portfolio optimisation, and disciplined future growth, while maintaining existing FY26 guidance. …
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has released its investor update for the three months ended December 2025 (Q3 FY26), outlining progress across Medicare engagement, clinical evidence development, laboratory testing volumes, and governance. The update centres on activities supporting potential reinstatement of US …
Pacific Edge (NZX:PEB) recordedoperating revenueof USD 5.9M for the six months to 30 September 2025 (1H FY26), down from USD 10.9M in 2H FY25, following the loss of Medicare coverage. Totalrevenuedeclined to USD 7.1M from USD 12.5M. Revenue from Medicare-related tests cannot be recognized …
Vital Healthcare Property Trust (NZX:VHP) has announced a conditional agreement to internalise its management structure through the retirement of Northwest Healthcare Properties Management Limited as manager. The internalisation process is intended to transition management responsibilities into a new governance framework, with arrangements negotiated by …
Ryman Healthcare (NZX:RYM) (ASX:RYM) established in Christchurch in 1984, manages 49 retirement villages across New Zealand and Australia, accommodating 15,200 residents and employing 7,800 staff. For the three months ended 30 September 2025, Ryman Healthcare reported 367 occupation right agreement (ORA) sales, comprising 93 …
Fisher & Paykel Healthcare received bullish ratings from both Jefferies and Macquarie despite softer FY2026 guidance.
Please wait processing your request...